ProCE Banner Activity

KEYNOTE-427 (Cohort A): Phase II Study of Pembrolizumab Monotherapy for First-line Treatment of Patients With Advanced Clear-Cell Renal Cell Carcinoma

Slideset Download
Conference Coverage
Pembrolizumab active in the first-line setting for patients with advanced ccRCC with no unexpected toxicities.

Released: June 06, 2018

Expiration: June 05, 2019

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

Astellas Text

AstraZeneca

Celgene

Eisai

Genentech TEXT Only

Janssen

Merck Oncology

Seagen